Table 1 Baseline characteristics and associations with hand dexterity.
From: Hand dexterity, daily functioning and health-related quality of life in kidney transplant recipients
Ā | Total population Nā=ā309 | Results of linear regression analyses | |||
---|---|---|---|---|---|
Univariable analyses | Analyses adjusted for sex and age | ||||
St. β (95% CI) | P | St. β (95% CI) | P | ||
Demographics | Ā | Ā | Ā | Ā | Ā |
Ā Ā Ā Male sex, n (%) | 180 (58) | 0.29 (0.18 to 0.40) | ā<ā0.001 | ā | ā |
Ā Ā Ā Age, years | 56ā±ā13 | 0.44 (0.34 to 0.54) | ā<ā0.001 | ā | ā |
Educational level, n (%) | Ā | Ā | Ā | Ā | Ā |
Ā Ā Ā Low | 114 (38) | Reference | n/a | Reference | n/a |
Ā Ā Ā Medium | 114 (38) | āā0.21 (āā0.33 to āā0.08) | 0.001 | āā0.09 (āā0.20 to 0.02) | 0.1 |
Ā Ā Ā High | 304 (25) | āā0.20 (āā0.33 to āā0.08) | 0.001 | āā0.18 (āā0.29 to āā0.07) | ā<ā0.001 |
Caucasian, n (%) | 297 (4) | āā0.08 (āā0.19 to 0.04) | 0.2 | āā0.08 (āā0.17 to 0.02) | 0.1 |
Body mass index, kg/m2 | 28ā±ā5 | 0.07 (āā0.04 to 0.18) | 0.2 | 0.11 (0.01 to 0.21) | 0.025 |
Primary kidney disease, n (%) | Ā | Ā | Ā | Ā | Ā |
Ā Ā Ā Unknown | 46 (15) | Reference | n/a | Reference | n/a |
Ā Ā Ā Inflammatory disease | 103 (33) | 0.02 (āā0.14 to 0.18) | 0.8 | 0.03 (āā0.11 to 0.16) | 0.7 |
Ā Ā Ā Congenital and hereditary kidney disease | 83 (27) | āā0.13 (āā0.28 to 0.03) | 0.1 | āā0.13 (āā0.26 to 0.01) | 0.062 |
Ā Ā Ā Kidney vascular disease, excl. vasculitis | 27 (9) | 0.02 (āā0.11 to 0.15) | 0.8 | āā0.02 (āā0.13 to 0.10) | 0.8 |
Ā Ā Ā Diabetic kidney disease | 20 (7) | 0.17 (0.04 to 0.30) | 0.010 | 0.17 (0.06 to 0.28) | 0.003 |
Ā Ā Ā Other | 30 (10) | āā0.02 (āā0.15 to 0.12) | 0.8 | āā0.03 (āā0.14 to 0.09) | 0.6 |
Diabetes, n (%) | 86 (28) | 0.22 (0.11 to 0.33) | ā<ā0.001 | 0.17 (0.08 to 0.27) | ā<ā0.001 |
Anemia, n (%) | 96 (31) | 0.08 (āā0.03 to 0.19) | 0.2 | 0.11 (0.01 to 0.20) | 0.032 |
Lifestyle parameters | Ā | Ā | Ā | Ā | Ā |
Alcohol intake, units/week, n (%) | Ā | Ā | Ā | Ā | Ā |
Ā Ā Ā None | 109 (37) | Reference | n/a | Reference | n/a |
Ā Ā Ā ā<ā7 units/week | 118 (41) | āā0.09 (āā0.22 to 0.04) | 0.2 | āā0.07 (āā0.19 to 0.04) | 0.2 |
Ā Ā Ā āā„ā7 units/week | 64 (22) | āā0.03 (āā0.16 to 0.11) | 0.7 | āā0.09 (āā0.21 to 0.02) | 0.1 |
Smoking history, n (%) | 150 (49) | āā0.03 (āā0.09 to 0.14) | 0.6 | āā0.07 (āā0.17 to 0.03) | 0.2 |
Transplant-specific characteristics | Ā | Ā | Ā | Ā | Ā |
Dialysis before transplantation, n (%) | 188 (61) | 0.16 (0.05 to 0.27) | 0.006 | 0.11 (0.01 to 0.21) | 0.025 |
Living donor, n (%) | 171 (55) | āā0.17 (āā0.29 to āā0.06) | 0.002 | āā0.08 (āā0.17 to 0.02) | 0.1 |
Delayed graft functioning, n (%) | 32 (11) | 0.09 (-0.02 to 0.21) | 0.1 | 0.03 (āā0.06 to 0.13) | 0.5 |
Time after transplantation, yearsā | 4 [1 to 11] | 0.07 (āā0.04 to 0.18) | 0.2 | 0.04 (āā0.05 to 0.14) | 0.4 |
History of rejection(s), n (%) | 31 (10) | 0.07 (āā0.05 to 0.18) | 0.2 | 0.09 (āā0.01 to 0.19) | 0.064 |
Postoperative CMV infection, n (%) | 44 (15) | 0.08 (āā0.03 to 0.20) | 0.2 | 0.04 (āā0.06 to 0.14) | 0.4 |
Patient reported outcome measurements | Ā | Ā | Ā | Ā | Ā |
Feeling of anxiety, n (%) | 68 (23) | 0.01 (āā0.10 to 0.13) | 0.8 | 0.06 (āā0.04 to 0.16) | 0.2 |
Moderate to severe depressive symptoms, n (%) | 15 (5) | āā0.10 (āā0.21 to 0.02) | 0.097 | āā0.05 (āā0.15 to 0.05) | 0.3 |
Laboratory measurements | Ā | Ā | Ā | Ā | Ā |
Hemoglobin, g/dL | 13.5ā±ā1.8 | 0.03 (āā0.14 to 0.09) | 0.7 | āā0.15 (āā0.25 to āā0.05) | 0.004 |
Leukocyte count, 109/L | 7.5ā±ā2.2 | 0.01 (āā0.10 to 0.13) | 0.8 | 0.02 (āā0.07 to 0.12) | 0.6 |
C-reactive protein, mg/Lā” | 1.9 [0.7 to 4.1] | 0.14 (0.03 to 0.25) | 0.014 | 0.11 (0.01 to 0.21) | 0.025 |
Plasma albumin, g/dL | 4.3ā±ā0.3 | āā0.18 (āā0.29 to āā0.07) | 0.002 | āā0.11 (āā0.21 to āā0.01) | 0.025 |
eGFR, mL/min/1.73m2 | 52ā±ā17 | āā0.11 (āā0.22 to 0.01) | 0.064 | āā0.07 (āā0.17 to 0.02) | 0.1 |
Immunosuppressive drugs | Ā | Ā | Ā | Ā | Ā |
Prednisolone, n (%) | 300 (97) | 0.11 (āā0.00 to 0.22) | 0.06 | 0.08 (āā0.02 to 0.17) | 0.1 |
Calcineurin inhibitor, n (%) | 255 (83) | āā0.08 (āā0.19 to 0.04) | 0.2 | āā0.01 (āā0.11 to āā0.09) | 0.9 |
Proliferation inhibitor, n (%) | 267 (86) | āā0.07 (āā0.18 to 0.05) | 0.2 | āā0.06 (āā0.16 to 0.04) | 0.2 |
mTOR inhibitor, n (%) | 12 (4) | āā0.05 (āā0.17 to 0.06) | 0.4 | āā0.04 (āā0.14 to 0.05) | 0.4 |